医学
米多司他林
肿瘤科
髓系白血病
内科学
化疗
生存分析
危险系数
人口
随机对照试验
安慰剂
比例危险模型
阿糖胞苷
髓样
临床研究阶段
化疗方案
总体生存率
外科
临床试验
维持疗法
作者
Sameer Bhimani,Taimoor Nasir,Aniqa Baloch,Swapnil Sunil Surpur,Satish Ahuja,Waleed Iftikhar,Muhammad Umair Anjum,Douglas Klamp
标识
DOI:10.1200/jco.2026.44.16_suppl.e18505
摘要
e18505 Background: FLT3 inhibitors improve outcomes in FLT3-mutated acute myeloid leukemia (AML); however, no head-to-head phase III comparisons exist among available agents. Updated randomized data from RATIFY (midostaurin), QUANTUM-First (quizartinib), and ADMIRAL (gilteritinib) enable indirect comparative effectiveness assessment of FLT3-directed therapy across treatment settings. Methods: A frequentist network meta-analysis was performed using phase III randomized trials enrolling FLT3-mutated AML patients. Reported hazard ratios (HRs) for overall survival (OS) and event-free survival (EFS) were extracted. Random-effects network models estimated treatment effects versus chemotherapy and ranking probabilities (P-scores). The evidence network was anchored through shared chemotherapy control arms. Frontline survival comparisons included RATIFY and QUANTUM-First; ADMIRAL was analyzed separately due to relapse/refractory (R/R) population differences. Results: Across five comparisons (~1,600 patients), midostaurin (HR 0.78; 95% CI 0.63–0.96) and quizartinib (HR 0.78; 95% CI 0.62–0.98) each significantly reduced mortality versus placebo in frontline AML. Indirect comparison demonstrated no detectable difference between the two agents (HR 1.00; 95% CI 0.73–1.36). Ranking analysis assigned near-identical P-scores to midostaurin and quizartinib (0.74 vs 0.74), supporting equivalent likelihood of benefit in the frontline setting. In the R/R population, gilteritinib significantly improved survival compared with salvage chemotherapy (HR 0.64; 95% CI 0.49–0.83). Conclusions: Midostaurin and quizartinib demonstrate equivalent survival probability in frontline FLT3-mutated AML based on current randomized evidence, challenging assumptions of superiority among FLT3 inhibitors. Gilteritinib remains an effective salvage option in relapsed disease but reflects a distinct treatment setting rather than comparative frontline potency. Interpretation is limited by cross-trial differences in age eligibility, FLT3 subtype inclusion, chemotherapy backbones, and trial era, which may affect transitivity assumptions in this network meta-analysis. This frequentist network meta-analysis incorporates mature survival updates from RATIFY and QUANTUM-First and demonstrates near-identical ranking probabilities (P-scores 0.74 vs 0.74), supporting equivalent frontline survival benefit of midostaurin and quizartinib. Future head-to-head trials incorporating MRD response and transplant-adjusted outcomes are warranted to refine sequencing strategies for FLT3-directed therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI